CN103848798B - 2-芳基硒唑化合物及其药物组合物 - Google Patents

2-芳基硒唑化合物及其药物组合物 Download PDF

Info

Publication number
CN103848798B
CN103848798B CN201210504310.8A CN201210504310A CN103848798B CN 103848798 B CN103848798 B CN 103848798B CN 201210504310 A CN201210504310 A CN 201210504310A CN 103848798 B CN103848798 B CN 103848798B
Authority
CN
China
Prior art keywords
methyl
selenazole
substituted
carboxylic acid
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210504310.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103848798A (zh
Inventor
史东方
傅长金
吴捷
刘俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ministry Of Health And Nanjing Pharmaceutical Co ltd
Atom Therapeutics Co Ltd
Original Assignee
Zhenjiang New Element Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhenjiang New Element Pharmaceutical Technology Co Ltd filed Critical Zhenjiang New Element Pharmaceutical Technology Co Ltd
Priority to CN201210504310.8A priority Critical patent/CN103848798B/zh
Priority to PCT/CN2013/087736 priority patent/WO2014082548A1/zh
Priority to US14/648,664 priority patent/US9802907B2/en
Priority to EP13858539.3A priority patent/EP2927219B1/en
Priority to JP2015544335A priority patent/JP6143877B2/ja
Publication of CN103848798A publication Critical patent/CN103848798A/zh
Application granted granted Critical
Publication of CN103848798B publication Critical patent/CN103848798B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/02—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms not condensed with other rings
    • C07D293/04—Five-membered rings
    • C07D293/06—Selenazoles; Hydrogenated selenazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201210504310.8A 2012-11-30 2012-11-30 2-芳基硒唑化合物及其药物组合物 Active CN103848798B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201210504310.8A CN103848798B (zh) 2012-11-30 2012-11-30 2-芳基硒唑化合物及其药物组合物
PCT/CN2013/087736 WO2014082548A1 (zh) 2012-11-30 2013-11-24 2-芳基硒唑化合物及其药物组合物
US14/648,664 US9802907B2 (en) 2012-11-30 2013-11-24 2-aryl selenazole compound and pharmaceutical composition thereof
EP13858539.3A EP2927219B1 (en) 2012-11-30 2013-11-24 2-aryl selenazole compound and pharmaceutical composition thereof
JP2015544335A JP6143877B2 (ja) 2012-11-30 2013-11-24 ２−アリールセレナゾール化合物及びその薬剤組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210504310.8A CN103848798B (zh) 2012-11-30 2012-11-30 2-芳基硒唑化合物及其药物组合物

Publications (2)

Publication Number Publication Date
CN103848798A CN103848798A (zh) 2014-06-11
CN103848798B true CN103848798B (zh) 2016-01-06

Family

ID=50827179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210504310.8A Active CN103848798B (zh) 2012-11-30 2012-11-30 2-芳基硒唑化合物及其药物组合物

Country Status (5)

Country Link
US (1) US9802907B2 (enExample)
EP (1) EP2927219B1 (enExample)
JP (1) JP6143877B2 (enExample)
CN (1) CN103848798B (enExample)
WO (1) WO2014082548A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936693B (zh) * 2013-01-22 2016-06-15 沈阳药科大学 2-(3-氰基-4-取代苯基)-4-甲基-1,3-硒唑-5-甲酸及其酯类化合物和制备方法
CN108358866B (zh) * 2017-01-12 2021-03-23 江西同和药业股份有限公司 一种非布司他中间体的制备方法及其在制备非布司他中的应用
CN111662239B (zh) * 2019-03-06 2023-07-28 中国医学科学院药物研究所 1,2,4-三唑类化合物及其制法和药物用途
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
CN102781924A (zh) * 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
CN103130744A (zh) * 2012-08-28 2013-06-05 沈阳药科大学 一种硒唑甲酸类化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3113110B2 (ja) 1993-01-19 2000-11-27 帝人株式会社 イソキサゾールおよびイソチアゾール誘導体
AU703609B2 (en) 1995-04-07 1999-03-25 Teijin Limited Protective agent for organ or tissue
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JPH10310578A (ja) 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
CN1993367B (zh) 2004-06-14 2012-05-30 日本化学医药株式会社 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
US7820700B2 (en) 2004-08-27 2010-10-26 Astellas Pharma Inc. 2-phenylpyridine derivative
EP1783124A4 (en) 2004-08-27 2009-07-08 Astellas Pharma Inc 2-PHENYLTHIOPHENDERIVAT

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
CN102781924A (zh) * 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
CN103130744A (zh) * 2012-08-28 2013-06-05 沈阳药科大学 一种硒唑甲酸类化合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
新型抗痛风药物非布索坦;唐春雷 等;《中国新药杂志》;20090430;第18卷(第7期);577-581 *

Also Published As

Publication number Publication date
US9802907B2 (en) 2017-10-31
JP6143877B2 (ja) 2017-06-07
WO2014082548A1 (zh) 2014-06-05
EP2927219B1 (en) 2018-05-30
EP2927219A4 (en) 2016-07-06
US20150291543A1 (en) 2015-10-15
CN103848798A (zh) 2014-06-11
EP2927219A1 (en) 2015-10-07
JP2016500115A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
CN103848798B (zh) 2-芳基硒唑化合物及其药物组合物
JP2018526417A (ja) 高尿酸血症又は痛風の治療又は予防用化合物
CA2810102A1 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
CN103980267B (zh) 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
AU2001234089B2 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
CN106632245B (zh) 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用
JPS60163852A (ja) アナフイラキシーの遅反応物質の拮抗物質
AU2012270310B2 (en) 1,3-Di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
TW201843135A (zh) 胺基-芳基-苯甲醯胺化合物及其使用方法
JP7520394B2 (ja) 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
WO2015102369A1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
CN103848796A (zh) 一类氘代2-苯基噻唑化合物及其药物组合物
JP7050009B2 (ja) ハロゲン化合物およびその軸性キラリティ異性体
CN106397408B (zh) 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
CN119320367B (zh) 取代噁二唑-苯胺类化合物及其用途
JP5932827B2 (ja) チアゾールアミン誘導体および抗ピコルナウイルス感染薬剤としてのその使用
WO2018001197A1 (zh) 一种尿酸转运体1抑制剂的制备方法
JPS6160656A (ja) ロイコトリエン拮抗剤
CN108069940B (zh) 硫代乙酸化合物、组合物及其应用
WO2021000527A1 (zh) 三环类xor抑制剂及其制备方法和应用
JP7450951B2 (ja) 新型ｆｘｒ小分子作動剤の製造およびその使用
CN120590351A (zh) 抗病毒素1,3-二氧代茚化合物
CN119039135B (zh) 羧基查尔酮类衍生物及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 212009 Zhenjiang city Jiangsu province area Dingmao Road No. 99 building 18 fifteen

Patentee after: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL Co.,Ltd.

Address before: 212009 Zhenjiang city Jiangsu province area Dingmao Road No. 99 building 18 fifteen

Patentee before: ATOM BIOSCIENCE AND PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190726

Address after: Room 502, East Building, 293 Shandong Road, Xuanwu District, Nanjing City, Jiangsu Province

Patentee after: The Ministry of health and Nanjing Pharmaceutical Co.,Ltd.

Address before: 212009 Zhenjiang city Jiangsu province area Dingmao Road No. 99 building 18 fifteen

Patentee before: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL Co.,Ltd.